Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIIb, Randomized, Open-label Study of the Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine Once Daily Compared to Atazanavir and Ritonavir Plus Tenofovir/Emtricitabine Once Daily in HIV-1 Infected Antiretroviral Therapy Naïve Women

NCT01910402 is registered in ClinicalTrials.gov with ViiV Healthcare as lead sponsor.

NCT NCT01910402
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01910402 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIIb, Randomized, Open-label Study of the Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine Once Daily Compared to Atazanavir and Ritonavir Plus Tenofovir/Emtricitabine Once Daily in HIV-1 Infected Antiretroviral Therapy Naïve Women
Lead sponsor
ViiV Healthcare
Phase
Phase 3
Overall status
Completed
Start date
August 22, 2013
Completion date
August 18, 2022
Enrollment
499 (actual)
Sites
90

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infections, infection, human immunodeficiency virus